Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Jyra Health vs ShapeIn Rx

Jyra Health
Graded #117

Higher grade

vs+9.199999999999996
ShapeIn Rx
Graded #323

Lower grade

The verdict

Jyra Health takes it — 69.6/100 to 60.4/100.

Jyra Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Jyra Health is an online weight-loss and longevity telehealth clinic offering compounded GLP-1 — semaglutide from $99/mo and tirzepatide from $133/mo (limited time) — prescribed by board-certified providers…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueShapeIn Rx +2
72
74
Dose & formulationJyra Health +7
64
57
Clinical oversightJyra Health +22
82
60
Labs & monitoringJyra Health +1
53
52
FulfillmentJyra Health +26
88
62
Contract termsJyra Health +8
49
41
Jyra Health · left barShapeIn Rx · right bar

The numbers

MetricJyra HealthShapeIn Rx
WeighScore69.6/10060.4/100
GradeCC
Scorecard rank#117#323
Semaglutide$99/mo (starting dose, plus a separate fee, compounded)$199/mo (compounded)
Tirzepatide$133/mo (starting dose, promotional rate, compounded)Not disclosed
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Jyra Health

Graded #117 · C

Strengths

  • Among the lowest compounded pricing — semaglutide from $99/mo and tirzepatide from $133/mo, with no membership and no hidden fees
  • Board-certified providers in all 50 states; no insurance required and free express delivery
  • Offers both compounded semaglutide and tirzepatide, plus a longevity track
  • Full legal suite published (Privacy, Terms, HIPAA, Refunds & Cancellations)

Where it loses points

  • The $133/mo tirzepatide price is flagged 'limited time' — verify current pricing before enrolling
  • Compounded medications are not FDA-approved (the site discloses this) — not brand Wegovy, Zepbound, Ozempic, or Mounjaro
  • Displays a self-hosted LegitScript badge but no verifiable seal or listing
  • Compounding pharmacy not named; appears to be a newer, smaller clinic (~300 patients/month)
ShapeIn Rx

Graded #323 · C

Strengths

  • One of the few telehealth providers offering compounded liraglutide as a daily alternative to weekly injections
  • Semaglutide is compounded with B12, and the combination is stated plainly
  • Publishes a street address and a staffed phone line with hours
  • States openly that telemedicine is limited to jurisdictions where its providers are licensed, rather than claiming all 50
  • LegitScript certification verified against the issued seal, not just the badge

Where it loses points

  • Advertises Trusted by 150k Americans and Excellent 4.8 with 150k happy customers, and neither figure is attributable to a verifiable review profile
  • No state list is published, only a statement that coverage is limited and a note that partner pharmacies may operate in all 50 states
  • The struck-through $199 next to $149 on the homepage reads as a discount but the two prices are different medications
  • Claims No Hidden Fees and No Monthly Membership while the Terms state subscriptions automatically renew
  • No compounding pharmacy is named, only US-Certified Pharmacy

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard